Anti-Human CD3 x GPRC5D (Talquetamab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Talquetamab. Talquetamab (JNJ-64407564) is a bispecific antibody that targets both CD3 on T-cells and GPRC5D on certain tumor cells.

Anti-Human CD3 x GPRC5D bispecific antibodies offer a promising therapeutic approach for multiple myeloma (MM) by targeting both T-cells and myeloma cells. GPRC5D (G protein- coupled receptor class C group 5 member D) is expressed in about 90% of malignant plasma cells in MM patients, making it an appealing target for treatment. Studies have shown that these bispecific antibodies effectively kill MM cells in both in vitro and in vivo settings, including in patients with relapsed or refractory disease. Their efficacy is linked to the levels of GPRC5D expression, and they have demonstrated significant tumor growth inhibition through the recruitment of T-cells. However, resistance mechanisms, such as genetic inactivation or epigenetic silencing of GPRC5D, have been observed in some patients. Despite these challenges, anti-CD3 x GPRC5D bispecific antibodies hold great potential as a potent treatment for a broad range of MM patients, either as a standalone therapy or in combination with other agents^1-3.

JNJ-64407564, also known as Talquetamab, is a first-in-class bispecific antibody targeting GPRC5D and CD3 for treating relapsed or refractory multiple myeloma (RRMM). In clinical trials, Talquetamab has demonstrated significant efficacy, with overall response rates exceeding 71% in patients exposed to at least three different classes of therapy. By redirecting T cells to attack GPRC5D-expressing myeloma cells, Talquetamab induces strong cytotoxic effects. The FDA granted Talquetamab accelerated approval in August 2023 for treating adults with RRMM who have undergone at least four prior lines of therapy, marking it as a promising new option for patients with limited treatment alternatives^2,4,5.

GPRC5D is predominantly expressed on malignant plasma cells, making it a promising target for multiple myeloma therapy.

CD3ε: TCR
GPRC5D: n/a

CD3ε: P07766
GPRC5D: Q9NZD1

1. Derrien J, Gastineau S, Frigout A, et al. Nat Cancer. 2023;4(11):1536-1543.
2. K P, S E, M M, et al. Blood. 2020;135(15).
3. Tomita U, Ishimoto Y, Ri M, et al. Sci Rep. 2024;14(1):5135.
4. Chari A, Krishnan A, Rasche L, et al. Clin Lymphoma Myeloma Leuk. 2024;24(10):665-693.e14.
5. Keam SJ. Talquetamab: First Approval. Drugs. 2023;83(15):1439-1445.
6. Talquetamab Humanized Recombinant Monoclonal Antibody (MA5-41863). Accessed October 4, 2024. https://www.thermofisher.com/antibody/product/Talquetamab-Humanized-Antibody-Recombinant-Monoclonal/MA5-41863